Equine IL-1 beta Recombinant Protein

Catalog Number:: RP0060E
Availability:: In stock
Application:: Cell Culture, ELISA Standard, ELISpot Control, Western Blot Control
100% Homology:: Equus asinus (ass), Equus caballus (horse)

Product Description

Equine IL-1β (catalog RP0060E) is a yeast-derived cytokine supplied lyophilized without carrier protein in 10% trehalose; it has no affinity tags and is naturally endotoxin-free, and should be reconstituted in sterile PBS that contains at least 0.1% carrier protein. The protein is ~17.3 kDa, 153 amino acids long (full sequence provided), and >98% pure by SDS-PAGE, with 100% amino-acid homology across horse and donkey. Store at -20°C (stable up to twelve months from date of receipt; working aliquots with carrier protein stable at least 3 months) and avoid repeated freeze/thaw cycles. Product origin is the USA. Kingfisher Biotech products are supplied for research applications and are not intended for medicinal, diagnostic, or therapeutic use. It is commonly used in immunology and cell-biology research to study IL-1β signaling, inflammation, inflammasome/pyroptosis and innate immune responses; typical experimental uses include cell-culture stimulation and dosing studies, cytokine and inflammasome assays, ELISA and neutralization assays, receptor-binding and signaling studies, flow-cytometry and Western blot controls, and antibody generation/validation.

Specifications

Amino Acid Sequence	AAVHSVNCRL RDIYHKSLVL SGACELQAVH LNGENTNQQV VFCMSFVQGE EETDKIPVAL GLKEKNLYLS CGMKDGKPTL QLETVDPNTY PKRKMEKRFV FNKMEIKGNV EFESAMYPNW YISTSQAEKK PVFLGNTRGG RDITDFIMEI TSA (153)
Endotoxin	Naturally endotoxin-free

Properties

Storage Conditions	-20°C
Molecular Weight	17.3 kDa
Purity	>98% as visualized by SDS-PAGE analysis.
Country Of Origin	USA

Background Info

Equine Interleukin-1 Beta (IL-1β) is a potent pro-inflammatory cytokine produced primarily by activated macrophages, monocytes, dendritic cells, and synoviocytes in horses (Equus caballus) in response to infection, tissue injury, or inflammatory stimuli. Synthesized as an inactive precursor (pro-IL-1β), it is cleaved into its active form by caspase-1 within the inflammasome complex and signals through the IL-1 receptor (IL-1R1), activating NF-κB and MAPK pathways that promote fever, leukocyte recruitment, endothelial activation, and acute-phase protein production. In equine health, IL-1β plays a central role in inflammatory conditions such as osteoarthritis, laminitis, colitis, endotoxemia, equine asthma (recurrent airway obstruction), and bacterial infections, where excessive IL-1β production contributes to joint degradation, pulmonary inflammation, systemic inflammatory response syndrome (SIRS), and tissue damage. In joint disease specifically, IL-1β drives cartilage matrix degradation and synovial inflammation, making it a key therapeutic target. As both a biomarker and mediator of inflammation, equine IL-1β is widely studied in veterinary medicine and performance horse management. In translational research, horses serve as valuable large-animal models for human osteoarthritis, sepsis, and inflammatory lung disease, and characterization of equine IL-1β supports studies of inflammasome activation, cytokine-driven pathology, and development of targeted anti-inflammatory and regenerative therapies relevant to both equine and human health.

Choose a size

Please choose a size to see price

RELATED MEDIA